Поражение сердечно-сосудистой системы на фоне терапии лекарственными средствами, влияющими на аппетит и массу тела

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults. 1999–2000. JAMA 2002; 288:1723-7.
2. NHLBI Expert Panel in the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. ObesRes 1998; 6 (Suppl. 2): 51S–2909.
3. Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescription weight loss pills among US adults in 1996–1998. Ann Intern Med 2001; 134: 282–6.
4. Wilhelm C. Growing the market for antiobesity drugs. Chemical Market Reporter 2000; FR23–24.
5. Roerig IL, Mitchell JE, de Zwaan M. The eating disorders medicine cabinet revisited: a clinician's guide to appetite suppressants and diuretics. Int J Eat Disord 2003; 33: 443–57.
6. Connolly HM, McGoon M. Obesity drugs and the heart. Curr Prob Cardiol 1999; 24: 745–92.
7. Phentermine. http://www.fda.gov/cder/da/da.htm [accessed December 6, 2003].
8. Drug information: appetite esuppressants, sympathomimetics (systemic). http://www.nlm'nih.gov/medlineplus/druginfo/uspdi/202069.html[accessed August 10, 2003].
9. Phentermine. http://www.pdr.net/[accessed December 6, 2003].
10. Fenfluramine and exfenfiuramine. http://www.fda.gov/cder/da/da.htm [accessed December 6, 2003].
11. Douglas JG, Gough J, Preston PG et al. Long-term efficacy of fenfluramine in treatment of obesity. Lancet 1983; 1: 384–6.
12. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic poten tial in obesity. Drugs 1992; 43: 713–33.
13. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November1997. MMWR Morb Mortal Wkly Rep 1997; 46: 1061–6.
14. Mast ST, Gersing KR, Anstrom KJ et al. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001; 87: 989–93.
15. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther 1992; 51: 642–6.
16. Sibutramine. http://www.fda.gov/cder/da/da.htm [accessed December 6, 2003].
17. Sibutramine hydrochloride monohydrate. http://www.pdr.net/[accessed December 6, 2003].
18. Petition to the FDA to ban the diet drug sibutramine (Meridia) (HRG Publication#1613). http://www.citizen.org/publications/print_release.cfm>ID=7160 [accessed October 14, 2003].
19. Abbott Laboratories reassures patients of the efficacy and safety of Meridia (sibutramine) and denounces public citizen's petition to the US FDA as in correctand misleading. March 20, 2002. http://www.abbott.com/news/press_release.cfm id=353[accessed December 6, 2003].
20. Bach DS, Rissanen AM, Mendel CM et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999; 7: 363–9.
21. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270–9.
22. Kernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826–32.
23. Bupropion Sustained Release Tablets.http://www.pdr.net [accessed December 6, 2003].
24. Anderson JW, Greenway FL, Fujioka K et al. Bupropion SR enhances weight loss: a 48 week double blinded, placebo-controlled trial. Obes Res 2002; 10: 633–41.
25. Bray GA, Hollander P, Klein S et al. A 6-month randomized, placebo-controlled, dose ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722–33.
26. Topiramate tablets, http://www.pdr.net [accessed December 6, 2003].
27. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
28. Proietto J, Thornburn AW. The therapeutic potential of leptin. Expert Opin lnvestig Drugs 2003; 12: 373–8.
29. Rubin LJ, Barst RJ, Kaiser LR et al. Primary pulmonary hypertension. Chest 1993; 104: 236–50.
30. Gurtner HP. Aminorex and pulmonary hypertension: a review. Cor Vasa 1985; 27: 160–71.
31. Brenot F, Herve P, Petitpretz P et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537–41.
32. Abenhaim L, Moride Y, Brenot F et al. Appetitesuppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609–16.
33. Mark EJ, Patalas ED, Chang HT et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997; 337: 602–6.
34. Herve P, Launay JM, Scrobohaci ML et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249–54.
35. Rothman RB, Redmon B, Raatz SK et al. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am Cardiol 2000; 85: 913–16.
36. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: implication for primary pulmonary hypertension. Circulation 1999; 100: 869–75.
37. Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin hypothesis: lessons for the future in pathogenesis. Respir Res 2002; 3: 9–12.
38. Rich S. Primary pulmonary hypertension. Curr Treat Options Cardiovasc Med 2000; 2: 135–40.
39. Rich S, Shillington A, McLaughlin. Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary ulmonary hypertension. Am J Cardiol 2003; 92: 1366–8.
40. Connolly HM, Crary JL, McGoon MD et al. Valvular eart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581–8.
41. Kimmel SE, Keane MG, Crary JL et al. Detailed ехamination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. Am J Cardiol 1999; 84: 304–8.
42. Klein AL, Burstow DJ, Tajik AJ et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr 1990; 3: 54–63.
43. Reid CL, Gardin JM, Yunis C et al. Prevalence and clinic correlated of aortic and mitral regurgitation in a young adult population: the CARDIA Study [Abstract]. Circulation 1994; 90: 1'5–1'9.
44. Jick H, Vasilakis C, Weinrauch LA et al. A population-based study of appetite suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339: 719–24.
45. Khan MA, Herzog CA, St Peter JV et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998; 339: 713–8.
46. Weissman N, Tighe JF, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, orplacebo. N Engl J Med 1998; 339: 725–32.
47. Wee CC, Phillips RS, Aurigemma G et al. Risk of valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiogra phy before use of medication. Ann Intern Med 1998; 129: 870–4.
48. Jollis JG, Landolfo CK, Kisslo J et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000; 101: 207–7.
49. Burger AJ, Sherman HB, Charlamb MJ et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. Am Coll Cardiol 1999; 34: Ii53–8.
50. Wellman PJ, Maher TJ. Synergistic interactions between fenfluramine and phentermine. Int J Obes 1999; 23: 723–32.
51. Gardin JM, Schumacher D, Constantine G et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000; 283: 1703–9.
52. Shively BK, Roldan CA, Gill EA et al. Prevalence and determinants of valvulopathy in patients treated with fexfenfluramine. Circulation 1999; 100: 2161–7.
53. Weissman N, Panza A, Tighe F, Gwynne JT. Natural history of valvu1ar regurgitation 1 year after discontinuation of dexfenfluramine therapy: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 267–73.
54. Gardin JM, Weissman NI, Leung C et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001; 286: 2011–4.
55. Steffee CH, Singh HK, Chitwood WR. Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 1999; 8: 245–53.
56. Rothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836–41.
57. Bonow RO, Carabello B, de Leon AC et al. Guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association tasks force on practice guidelines. J Am_oll Cardiol 199B; 32: 1486–582.

И.Е.Чазова, Е.В.Ильина, С.Н.Терещенко

ФГУ РКНПК, ГОУ ВПО МГМСУ

________________________________________________

I.E.Chazova, E.V.Ilina, S.N.Tereshchenko

FSI Russian cardiology scientific and production complex, Moscow, Moscow state mediko-stomatologic university